Gomberg-Maitland M - Search Results

1

The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension.

Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz RP, Foreman AJ, Badesch DB, McGoon MD. Benza RL, et al. Chest. 2012 Feb;141(2):354-362. doi: 10.1378/chest.11-0676. Epub 2011 Jun 16. Chest. 2012. PMID: 21680644

2

Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.

Gomberg-Maitland M, Tapson VF, Benza RL, McLaughlin VV, Krichman A, Widlitz AC, Barst RJ. Gomberg-Maitland M, et al. Am J Respir Crit Care Med. 2005 Dec 15;172(12):1586-9. doi: 10.1164/rccm.200505-766OC. Epub 2005 Sep 8. Am J Respir Crit Care Med. 2005. PMID: 16151039 Clinical Trial.

3

Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial.

Tapson VF, Gomberg-Maitland M, McLaughlin VV, Benza RL, Widlitz AC, Krichman A, Barst RJ. Tapson VF, et al. Chest. 2006 Mar;129(3):683-8. doi: 10.1378/chest.129.3.683. Chest. 2006. PMID: 16537868 Clinical Trial.

4

Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension.

Gomberg-Maitland M, Huo D, Benza RL, McLaughlin VV, Tapson VF, Barst RJ. Gomberg-Maitland M, et al. J Heart Lung Transplant. 2007 Jul;26(7):732-8. doi: 10.1016/j.healun.2007.04.013. Epub 2007 Jun 13. J Heart Lung Transplant. 2007. PMID: 17613405 Clinical Trial.

5

A USA-based registry for pulmonary arterial hypertension: 1982-2006.

Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. Thenappan T, et al. Eur Respir J. 2007 Dec;30(6):1103-10. doi: 10.1183/09031936.00042107. Epub 2007 Sep 5. Eur Respir J. 2007. PMID: 17804449 Free article.

6

Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension.

Shah SJ, Thenappan T, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Shah SJ, et al. Circulation. 2008 May 13;117(19):2475-83. doi: 10.1161/CIRCULATIONAHA.107.719500. Epub 2008 May 5. Circulation. 2008. PMID: 18458173

7

Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension.

Shah SJ, Gomberg-Maitland M, Thenappan T, Rich S. Shah SJ, et al. Chest. 2009 Sep;136(3):694-700. doi: 10.1378/chest.08-2823. Epub 2009 Apr 6. Chest. 2009. PMID: 19349384

8

Tadalafil therapy for pulmonary arterial hypertension.

Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Galiè N, et al. Circulation. 2009 Jun 9;119(22):2894-903. doi: 10.1161/CIRCULATIONAHA.108.839274. Epub 2009 May 26. Circulation. 2009. PMID: 19470885 Clinical Trial.

9

Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension.

Hampole CV, Mehrotra AK, Thenappan T, Gomberg-Maitland M, Shah SJ. Hampole CV, et al. Am J Cardiol. 2009 Sep 15;104(6):868-72. doi: 10.1016/j.amjcard.2009.05.016. Am J Cardiol. 2009. PMID: 19733726

10

Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension.

Chandra S, Shah SJ, Thenappan T, Archer SL, Rich S, Gomberg-Maitland M. Chandra S, et al. J Heart Lung Transplant. 2010 Feb;29(2):181-7. doi: 10.1016/j.healun.2009.07.005. Epub 2009 Sep 26. J Heart Lung Transplant. 2010. PMID: 19783169

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

164 results

Search Page

Filters